Microalbuminuria is a frequent finding in several acute clinical conditions and predicts poor outcome; its role in acute ischemic stroke, however, is unknown. This study was designed to investigate the prevalence and predictive power of microalbuminuria in acute stroke patients and to establish the relationship between microalbuminuria and the patients’ clinical status. We studied 60 patients admitted within 24 h of their first ischemic stroke, 50 patients with a history of ischemic stroke, and 30 control subjects without known cerebrovascular diseases. Neurological deficit was assessed by the Scandinavian Stroke Scale (SSS) on admission and on days 1, 7, 14, and 30. Urinary albumin excretion was measured using immunonephelometric method, with 24-hour collections performed on day 2. Outcome was assessed by 30-day, 90-day and 1-year mortality. Microalbuminuria was found in 46.7% of patients with acute stroke, 16% of subjects with a history of stroke, and 16.7% of controls. On admission, acute stroke patients with microalbuminuria had more severe neurological deficit (median of SSS score on admission was 28 vs. 40, and on day 1, 22 vs. 39, both p < 0.05; Mann-Whitney U test) and more often had a decreased level of consciousness (32 vs. 10%, p < 0.05; Fisher exact test). Mortality was higher in the group of patients with microalbuminuria in acute stroke (21 vs. 3% after 30 days, 39 vs. 6% after 90 days and 50 vs. 9% after 1 year, p < 0.05 for all differences; Fisher exact test). In logistic regression analysis, microalbuminuria was found to be an independent predictor of 1-year mortality after ischemic stroke (OR = 6.0; p = 0.022; 95% CI = 1.3–27.7).

Haffner SM, Stern MP, Gruber KK, Hazuda HP, Mitchell BD, Patterson JK: Microalbuminuria: Potential marker for increased cardiovascular risk factors in nondiabetic subjects? Arteriosclerosis 1990;10:727–731.
Metcalf PA, Scragg RKR: Epidemiology of microalbuminuria in the general population. J Diabetes Complications 1994;8:157–163.
Parving HH: Microalbuminuria in essential hypertension and diabetes mellitus. J Hypertens 1996;14(suppl 2):S89–S94.
Viberti GC, Jarrett RJ, Mahmud U, Hill RD, Argyropoulos A, Keen H: Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus. Lancet 1982;i:1430–1432.
Messent JW, Elliot TG, Hill RD, Jarrett RJ, Keen H, Viberti GC: Prognostic significance of microalbuminuria in insulin-dependent diabetes mellitus: A twenty-three-year follow-up study. Kidney Int 1992;41:836–839.
Bigazzi R, Bianchi S, Baldari D, Campese VM: Microalbuminuria predicts cardiovascular events and renal insufficiency in patients with essential hypertension. J Hypertens 1998;16:1325–1333.
Ljungman S, Wikstrand J, Hartford M, Berglund G: Urinary albumin excretion: A predictor of risk of cardiovascular disease. Am J Hypertens 1996;9:770–778.
Damsgaard EM, Frøland A, Jørgensen OD, Mogensen CE: Microalbuminuria as predictor of increased mortality in elderly people. BMJ 1990;300:297–300.
Yudkin JS, Forrest RD, Jackson CA: Microalbuminuria as predictor of vascular disease in non-diabetic subjects. Lancet 1988;ii:530–533.
Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, Jensen T, Kofoed-Enevoldsen A: Albuminuria reflects widespread vascular damage: The Steno hypothesis. Diabetologia 1989;32:219–226.
Gosling P, Hughes EA, Reynolds TM, Fox JP: Microalbuminuria is an early response following myocardial infarction. Eur Heart J 1991;12:508–513.
Shearman CP, Gosling P, Walker KJ: Is low proteinuria an early predictor of severity of acute pancreatitis? J Clin Pathol 1989;42:1132–1135.
Roine I: Microalbuminuria: An index of severity in childhood meningitis. Pediatr Infect Dis J 1993;12:584–588.
Smith FC, Gosling P, Sanghera K, Green MA, Paterson IS, Shearman CP: Microproteinuria predicts the severity of systemic effects of reperfusion injury following infrarenal aortic aneurysm surgery. Ann Vasc Surg 1994;8:1–5.
Berton G, Citro T, Palmieri R, Petucco S, De Toni R, Palatini P: Albumin excretion rate increases during acute myocardial infarction and strongly predicts early mortality. Circulation 1997;96:3338–3345.
Report of the WHO Task Force on Stroke and Other Cerebrovascular Diseases: Stroke 1989:Recommendations on stroke prevention, diagnosis and therapy. Stroke 1989;20:1407–1431.
Scandinavian Stroke Study Group: Multicenter trial of hemodilution in ischemic stroke: Background and study protocol. Stroke 1985;16:885–890.
Guerrero-Romero F, Rodriguez-Moran M: Proteinuria is an independent risk factor for ischemic stroke in non-insulin-dependent diabetes mellitus. Stroke 1999;30:1787–1791.
Beamer NB, Coull BM, Clark WM, Wynn M: Microalbuminuria in ischemic stroke. Arch Neurol 1999;56:699–702.
Shearman CP, Gosling P, Gwynn BR, Simms MH: Systemic effects associated with intermittent claudication: A model to study biochemical aspects of vascular disease? Eur J Vasc Surg 1988;2:401–404.
Horton RC, Gosling P, Reeves CN, Payne M, Nagle RE: Microalbumin excretion in patients with positive exercise electrocardiogram tests. Eur Heart J 1994;15:1353–1355.
Baylis C: The aging kidney; in Jamison RL, Wilkinson R (eds): Nephrology. London, Chapman & Hall, 1997, pp 177–180.
Hörner D, Fliser D, Klimm HP, Ritz E: Albuminuria in normotensive and hypertensive individuals attending offices of general practitioners. J Hypertens 1996;14:655–660.
Jensen JS, Feldt-Rasmussen B, Borch-Johnsen K, Jensen G: Urinary albumin excretion in a population based sample of 1,011 middle aged non-diabetic subjects. Scand J Clin Lab Invest 1993;53:867–872.
Pallister I, Gosling P, Alpar K, Bradley S: Prediction of posttraumatic adult respiratory distress syndrome by albumin excretion rate eight hours after admission. J Trauma 1997;42:1056–1061.
Jensen T, Bjerre-Knudsen J, Feldt-Rasmussen B, Deckert T: Features of endothelial dysfunction in early diabetic nephropathy. Lancet 1989;i:461–463.
Pedrinelli R, Giampietro O, Carmassi F, Melillo E, Dell’Omo G, Catapano G, Matteucci E, Talarico L, Morale M, De Negri F, Di Bello V: Microalbuminuria and endothelial dysfunction in essential hypertension. Lancet 1994;344:14–18.
Nakayama T, Date C, Yokoyama T, Yoshike N, Yamaguchi M, Tananka H: A 15,5-year follow-up study of stroke in a Japanese provincial city: The Shibata Study. Stroke 1997;28:45–52.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.